Titan Medical Stock Forecast, Price & News

Titan Medical (NASDAQ:TMDI) Frequently Asked Questions

Is Titan Medical a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Medical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Titan Medical stock.
View analyst ratings for Titan Medical or view top-rated stocks.

How has Titan Medical's stock price been impacted by Coronavirus (COVID-19)?

Titan Medical's stock was trading at $0.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TMDI stock has increased by 250.7% and is now trading at $0.7013.
View which stocks have been most impacted by COVID-19.

Are investors shorting Titan Medical?

Titan Medical saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 712,600 shares, a decrease of 26.3% from the October 31st total of 967,300 shares. Based on an average trading volume of 626,700 shares, the short-interest ratio is presently 1.1 days.
View Titan Medical's Short Interest.

When is Titan Medical's next earnings date?

Titan Medical is scheduled to release its next quarterly earnings announcement on Monday, February 28th 2022.
View our earnings forecast for Titan Medical.

How were Titan Medical's earnings last quarter?

Titan Medical Inc. (NASDAQ:TMDI) announced its earnings results on Thursday, November, 11th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.02. During the same period in the previous year, the firm posted ($0.02) EPS.
View Titan Medical's earnings history.

What price target have analysts set for TMDI?

2 brokers have issued 12 month price targets for Titan Medical's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Titan Medical's stock price to reach $4.00 in the next year. This suggests a possible upside of 470.4% from the stock's current price.
View analysts' price targets for Titan Medical or view top-rated stocks among Wall Street analysts.

Who are Titan Medical's key executives?

Titan Medical's management team includes the following people:

• David J. McNally, President, Chief Executive Officer & Director
• Stephen L. Lemieux, Chief Financial Officer
• Perry A. Genova, Senior Vice President-Research & Development
• Deepak Basra, Vice President-Strategy & Business Development
• Chris Seibert, Vice President-Business Development

Who are some of Titan Medical's key competitors?

Some companies that are related to Titan Medical include Retractable Technologies (RVP), NeuroPace (NPCE), Westaim (WEDXF), Co-Diagnostics (CODX), CVRx (CVRX), DarioHealth (DRIO), Apollo Endosurgery (APEN), Profound Medical (PROF), Liquidia (LQDA), Cytosorbents (CTSO), TransEnterix (TRXC), iCAD (ICAD), TELA Bio (TELA), AIT Therapeutics (AITB) and Repro Med Systems (KRMD).
View all of TMDI's competitors.

What other stocks do shareholders of Titan Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Medical investors own include NIO (NIO), Advanced Micro Devices (AMD), Electrameccanica Vehicles (SOLO), Sorrento Therapeutics (SRNE), Ampio Pharmaceuticals (AMPE), Biocept (BIOC), Micron Technology (MU), Blink Charging (BLNK), Bionano Genomics (BNGO) and FuelCell Energy (FCEL).

What is Titan Medical's stock symbol?

Titan Medical trades on the NASDAQ under the ticker symbol "TMDI."

Who are Titan Medical's major shareholders?

Titan Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include Masters Capital Management LLC (1.35%), Essex LLC (1.34%), Morgan Stanley (0.16%), Two Sigma Advisers LP (0.08%), UBS Group AG (0.04%) and Reilly Financial Advisors LLC (0.03%).

Which institutional investors are selling Titan Medical stock?

TMDI stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, and Morgan Stanley.

Which institutional investors are buying Titan Medical stock?

TMDI stock was acquired by a variety of institutional investors in the last quarter, including Essex LLC, Masters Capital Management LLC, Reilly Financial Advisors LLC, UBS Group AG, and Strong Tower Advisory Services.

How do I buy shares of Titan Medical?

Shares of TMDI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Titan Medical's stock price today?

One share of TMDI stock can currently be purchased for approximately $0.70.

How much money does Titan Medical make?

Titan Medical has a market capitalization of $77.93 million and generates $20 million in revenue each year. The company earns $-24.18 million in net income (profit) each year or ($0.49) on an earnings per share basis.

How many employees does Titan Medical have?

Titan Medical employs 9 workers across the globe.

What is Titan Medical's official website?

The official website for Titan Medical is www.titanmedicalinc.com.

Where are Titan Medical's headquarters?

Titan Medical is headquartered at 155 UNIVERSITY AVENUE, TORONTO A6, M5H 3B7.

How can I contact Titan Medical?

Titan Medical's mailing address is 155 UNIVERSITY AVENUE, TORONTO A6, M5H 3B7. The company can be reached via phone at (416) 548-7522.